Evidence map›Paper›PMID 28063815›Full record

Trial reportThe lancet. HIV2017

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.

Jemma O'Connor, Michael J Vjecha, Andrew N Phillips, Brian Angus, David Cooper, Beatriz Grinsztejn, Gustavo Lopardo, Satyajit Das, Robin Wood, Aimee Wilkin and 10 more

2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The lancet. HIV, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00867048 phase4completednot on this map

Strategic Timing of AntiRetroviral Treatment

TypeinterventionalSponsorUniversity of MinnesotaRan2009 to 2022Enrolled4,688ConditionsHIV InfectionArmsAll licensed antiretroviral medications
NCT04712058 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests

TypeinterventionalSponsorNational Taiwan University HospitalRan2021 to 2023Enrolled200ConditionsHIV InfectionsArmsBictegravir / Emtricitabine / Tenofovir Alafenamide Oral Tablet [Biktarvy]
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025
    Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
  10. Article
  11. COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.International journal of chronic obstructive pulmonary disease · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 8 countries.

Jemma O'ConnorResearch Department of Infection and Population Health, University College London, London, UK.
Michael J VjechaVeterans Affairs Medical Center, Washington, DC, USA.
Andrew N PhillipsResearch Department of Infection and Population Health, University College London, London, UK. Electronic address: andrew.phillips@ucl.ac.uk.
Brian AngusOxford Centre for Clinical Tropical Medicine, Nuffield Department of Medicine, Oxford University, Oxford, UK.
David CooperThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Beatriz GrinsztejnSTD and AIDS Clinical Research Laboratory, Evandro Chagas Clinical Research Institute (IPEC), Rio de Janeiro, Brazil.
Gustavo LopardoFundación Centro de Estudios Infectológicos, Buenos Aires, Argentina.
Satyajit DasHIV and GU Medicine, Coventry and Warwickshire Partnership Trust, University of Warwick, Coventry, UK.
Robin WoodDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa.
Aimee WilkinSection on Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Hartwig KlinkerUniversity of Würzburg Medical Center, Department of Internal Medicine II, Würzburg, Germany.
Pacharee KantipongChaingrai Prachanukroh Hospital, Chaingrai, Thailand.
Karin L KlingmanDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
David JilichDepartment of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
Elbushra HeriekaRoyal Bournemouth Hospital, Bournemouth, UK.
Eileen DenningDivision of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Ibrahim AbubakarInstitute for Global Health, University College London, London, UK.
Fred GordinVeterans Affairs Medical Center, Washington, DC, USA; The George Washington University, Washington, DC, USA.
Jens D LundgrenDepartment of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
INSIGHT START study group
University College London · GBCharles University · CZFundación Centro de Estudios Infectológicos · ARGeorge Washington University · USNational Institute of Allergy and Infectious Diseases · USNuffield Orthopaedic Centre · GBRoyal Bournemouth Hospital · GBUniversity of Cape Town · ZAUniversity of Copenhagen · DKUniversity of Minnesota · USUniversity of Warwick · GBUniversity of Würzburg · DEUNSW Sydney · AUVeterans Health Administration · USWake Forest University · US

Funding

International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)UM1AI068641 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2011 to 2014
$83.5M
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): STARTUM1AI120197 · NIAID · UNIVERSITY OF MINNESOTA · PI NEATON, JAMES DENNIS · 2015 to 2017
$65.1M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Medical Research Council MC_UU_12023/23NIAID NIH HHS UM1 AI068641NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI120197
6 · The paper itself

Abstract

backgroundThe effects of antiretroviral therapy on risk of severe bacterial infections in people with high CD4 cell counts have not been well described. In this study, we aimed to quantify the effects of immediate versus deferred ART on the risk of severe bacterial infection in people with high CD4 cell counts in a preplanned analysis of the START trial.

methodsThe START trial was a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count of more than 500 cells per μL assigned to immediate ART or deferral until their CD4 cell counts were lower than 350 cells per μL. We used Cox proportional hazards regression to model time to severe bacterial infection, which was defined as a composite endpoint of bacterial pneumonia (confirmed by the endpoint review committee), pulmonary or extrapulmonary tuberculosis, or any bacterial infectious disorder of grade 4 severity, that required unscheduled hospital admissions, or caused death. This study is registered with ClinicalTrials.gov, number NCT00867048.

findingsPatients were recruited from April 15, 2009, to Dec 23, 2013. The data cutoff for follow-up was May 26, 2015. Of 4685 HIV-positive people enrolled, 120 had severe bacterial infections (immediate-initiation group n=34, deferred-initiation group n=86; median 2·8 years of follow-up). Immediate ART was associated with a reduced risk of severe bacterial infection compared with deferred ART (hazard ratio [HR] 0·39, 95% CI 0·26-0·57, p<0·0001). In the immediate-initiation group, average neutrophil count over follow-up was 321 cells per μL higher, and average CD4 cell count 194 cells per μL higher than the deferred-initiation group (p<0·0001). In univariable analysis, higher time-updated CD4 cell count (0·78, 0·71-0·85, p=0·0001) was associated with reduced risk of severe bacterial infection. Time-updated neutrophil count was not associated with severe bacterial infection. After adjustment for time-updated factors in multivariable analysis, particularly the CD4 cell count, the HR for immediate-initiation group moved closer to 1 (HR 0·84, 0·50-1·41, p=0·52). These results were consistent when subgroups of the severe bacterial infection composite were analysed separately.

interpretationImmediate ART reduces the risk of several severe bacterial infections in HIV-positive people with high CD4 cell count. This is partly explained by ART-induced increases in CD4 cell count, but not by increases in neutrophil count.

fundingNational Institute of Allergy and Infectious Diseases National Institutes of Health, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales, Bundesministerium für Bildung und Forschung, European AIDS Treatment Network, Australian National Health and Medical Research Council, UK National Institute for Health Research and Medical Research Council, Danish National Research Foundation.

Indexed as

Antiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAustraliaBacterial InfectionsDrug Administration ScheduleFemaleHIV InfectionsHumansMaleMiddle AgedPneumonia, BacterialProportional Hazards ModelsRegression AnalysisAnti-HIV Agents

Identifiers

PMID28063815
PMCPMC5337625
OpenAlexW2568302821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.